TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $49,905 | -31.7% | 3,249 | 0.0% | 0.01% | -36.4% |
Q1 2023 | $73,070 | +6.9% | 3,249 | 0.0% | 0.01% | 0.0% |
Q4 2022 | $68,326 | -1.0% | 3,249 | +16.4% | 0.01% | 0.0% |
Q3 2022 | $69,000 | -9.2% | 2,792 | -11.2% | 0.01% | -8.3% |
Q2 2022 | $76,000 | -6.2% | 3,143 | 0.0% | 0.01% | +9.1% |
Q1 2022 | $81,000 | -23.6% | 3,143 | -8.2% | 0.01% | -15.4% |
Q4 2021 | $106,000 | +27.7% | 3,424 | 0.0% | 0.01% | +18.2% |
Q3 2021 | $83,000 | +66.0% | 3,424 | 0.0% | 0.01% | +57.1% |
Q2 2021 | $50,000 | -20.6% | 3,424 | +34.8% | 0.01% | -22.2% |
Q1 2021 | $63,000 | -7.4% | 2,541 | +2.3% | 0.01% | -18.2% |
Q4 2020 | $68,000 | – | 2,484 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |